Market Report, "Slovenia Pharmaceuticals & Healthcare Report Q2 2011", published

Fast Market Research recommends "Slovenia Pharmaceuticals & Healthcare Report Q2 2011" from Business Monitor International, now available
Spread the Word
Listed Under



Massachusetts - US

March 24, 2011 - PRLog -- In BMI's Business Environment Ratings (BERs) table for Q211, Slovenia ranks tenth of the 20 markets in the Emerging Europe region. Globally, Slovenia ranks 43rd out of the 83 pharmaceutical markets surveyed by BMI.

Health expenditure in Slovenia reached a value of EUR3.07bn (US$4.09bn) in 2010. By 2015, experiencing a low 2.85% compound annual growth rate (CAGR) in local currency terms, it is calculated the sector will be worth EUR3.54bn (US$4.42bn), as the authorities rationalise spending and introduce a range of cost-containment measures that will also hinder pharmaceutical expenditure under the publicly subsidised system. Health expenditure per capita at consumer prices reached a substantial value of US$1,978 in 2010. By 2015, per-capita spending on healthcare is expected to rise to US$2,131, as a result of the changing US dollar:euro exchange rate. Through to 2020, however, per capita spend will rise to US$2,363, as overall healthcare spending posts a 10-year CAGR of 1.79%.

In December 2010, Slovenia's Health Insurance Institute (ZZZS) updated the country's drug reimbursement list. The latest list features several new innovative drugs, including several for type 2 diabetes, but there are also new generic medicines and changes to the maximum prices for particular active pharmaceutical ingredients in groups of interchangeable products. Local analysts believe such initiatives will save around EUR9mn (US$11.8mn) annually.

The ZZZS also announced in December 2010 that it had prepared a package of reforms relating to pharmaceutical prices, interchangeable drugs and advertising. The ZZZS also voiced concerns regarding overprescribing for elderly patients. In addressing these concerns, the Ministry of Health announced that it would launch a prescription drug database to monitor prescriptions to individuals. While the full nature of reform measures has not been made public, it is anticipated that they will have the same impact as the June 2010 cost-containment measures.

Nevertheless, main local companies Krka and Lek will continue to be keen on intensifying their foreign operations, especially in relation to new markets such as Russia and Romania. The companies are also seeking to increase their presence in the Commonwealth of Independent States (CIS), Central & Eastern Europe (CEE), Western Europe and North America.

In November 2010, Krka announced that it is set to invest EUR135mn (US$185mn) in expanding its Russian operations through to 2015. The company currently manufactures 720mn medicine tablets and capsules per year in Russia and plans to triple this volume over the next five years. Krka has invested EUR40mn (US$55mn) in its Russian subsidiaries since 2003, and plans to invest EUR86mn (US$118mn) in the next three years, with the remaining EUR49mn (US$67mn) over the following two years.

For more information or to purchase this report, go to:

Partial Table of Contents:

SWOT Analysis
- Slovenia Pharmaceuticals And Healthcare Industry SWOT
- Slovenia Political SWOT
- Slovenia Economic SWOT
- Slovenia Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Emerging Europe - Regional Pharma Business Environment Ratings for Q211
- Rewards
- Risks
Slovenia - Market Summary
Regulatory Regime
- Recent EU-Wide Regulatory Developments
- Intellectual Property Regime
- IP Deficiencies
- Pricing Regime
- Reimbursement Regime
- Recent Pricing and Reimbursement Developments
- Eurozone Entry
Industry Developments
- Epidemiology
- Table: Disease Burden In CEE
- Healthcare Sector
- Healthcare Provision Developments
- Regional Healthcare Collaboration
- Healthcare Expenditure
- Healthcare Insurance
- Recent Healthcare Insurance Developments
- Clinical Trials
- Biotechnology
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Health Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Slovenia - Economic Activity, 2006-2015
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Sales Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Device Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Imports & Exports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Table: Leading Companies In Slovenia. 2009
Company Monitor
- Local Company Profiles
- Krka
- Lek (Novartis/Sandoz)
- Multinational Company Profiles
- GlaxoSmithKline
- Sanofi-Aventis
- Pfizer
- Novartis
- Merck & Co
Country Snapshot: Slovenia Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030

Full Table of Contents is available at:

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Health, Pharmaceutical, Drug, Healthcare, Zzzs, Krka, Invest, Prescription, Cagr, Interchangeable
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share